Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Background The REVEAL model for pulmonary arterial hypertension (PAH) uses 19 predictors to calculate a 1-year survival probability and can be repeated over time. It is currently unclear which of the 19 variables are the most essential for serial REVEAL score calculation. We aimed to identify high-yield predictors in the REVEAL score and hypothesized that the model could be simplified considerably without compromising performance. Methods REVEAL scores were calculated in a cohort of 140 PAH patients (Full REVEAL Model). Scores were then recalculated excluding all right heart catheterization and pulmonary function test data (Simple Model) and again using only PAH type, New York Heart Association class, brain natriuretic peptide, renal function and right atrial pressure by echocardiogram (Clinical Model). The models were then tested for the ability to predict 1-year outcomes and the performance of the models was compared. Results The c indices of the models to predict 1-year survival were not statistically different from one another (Full REVEAL Model: 0.765; Simple Model: 0.759; Clinical Model: 0.745; p = 0.92). For the composite outcome of survival or freedom from lung transplant at 1 year, the models were again not statistically different from one another (c indices: Full REVEAL Model: 0.805; Simple Model: 0.809; Clinical Model: 0.785; p = 0.73). Conclusions The original, Full REVEAL Model appeared to have comparable performance after selectively limiting the number of predictors. There is opportunity to re-evaluate large-registry PAH data to identify a limited number of high-yield variables and to develop a simplified, clinical model.

Original languageEnglish (US)
Pages (from-to)382-387
Number of pages6
JournalJournal of Heart and Lung Transplantation
Issue number4
StatePublished - Apr 2014

Bibliographical note

Funding Information:
T.D. serves as a consultant for Actelion, Gilead and United Therapeutics, and receives grant support from Novartis and United Therapeutics. The other authors have no conflicts of interest to disclose.

Copyright 2014 Elsevier B.V., All rights reserved.


  • prediction model
  • pulmonary arterial hypertension
  • survival


Dive into the research topics of 'Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters'. Together they form a unique fingerprint.

Cite this